FDA — authorised 30 January 1987
- Application: ANDA071295
- Marketing authorisation holder: ABBVIE
- Local brand name: ATROPINE
- Indication: SOLUTION — INTRAMUSCULAR
- Status: approved
🇺🇸 Enlon-Plus in United States
FDA authorised Enlon-Plus on 30 January 1987
Marketing authorisations
FDA — authorised 6 November 1991
- Application: NDA019678
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: ENLON-PLUS
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 November 1991
- Application: NDA019677
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: ENLON-PLUS
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 January 2002
- Application: NDA021175
- Marketing authorisation holder: US ARMY
- Local brand name: ATNAA
- Indication: INJECTABLE — INTRAMUSCULAR
- Status: approved
FDA — authorised 28 September 2006
- Application: NDA021983
- Marketing authorisation holder: MMT
- Local brand name: DUODOTE
- Indication: INJECTABLE — INTRAMUSCULAR
- Status: approved
FDA
- Status: approved
Enlon-Plus in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Ophthalmology approved in United States
Frequently asked questions
Is Enlon-Plus approved in United States?
Yes. FDA authorised it on 30 January 1987; FDA authorised it on 6 November 1991; FDA authorised it on 6 November 1991.
Who is the marketing authorisation holder for Enlon-Plus in United States?
ABBVIE holds the US marketing authorisation.